Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| This is going to be, again, a large pool, it is prevention, so clearly there is a really good opportunity for us |
| We are excited by the potential for new product launches in these regions |
| In diversified, we saw another quarter of healthy performance, particularly in neurology as we continued to capitalize on opportunities in the market created by competitor supply constraints |
| and EMEA, we believe Solta Medical is positioned for continued near and long term growth globally |
| Revenue growth was driven by strong demand in China, including the effective comparison to 2022 when China, and to a lesser degree the rest of the Asia Pacific region were affected by COVID-related lockdowns |
| Neurology delivered year-over-year growth as we continued to capitalize on opportunities in the market created by supply constraints among competing products in the fourth quarter |
| We grew our company and delivered or exceeded our guidance |
| As we discussed on this call, we had a solid Q4 and 2023 |
| As Tom mentioned, Cabtreo was launched and available for patients as of late January 2024, and in addition to the important benefits this product is expected to bring patients, we view this as an opportunity to return the dermatology business to growth |
| But if we look at our data, again we think it’s positive and we think we have a really interesting product here |
| I am pleased with the continued momentum in our pipeline |
| But overall, the TRx growth as we looked at it for the year was strong, and when we looked at the fourth quarter on the IBS-D side, we were exiting at much higher than what the full year looked like |
| For the quarter, Relistor delivered 44% growth over the prior year due to both higher demand and improved net pricing, while Trulance revenues were flat as TRx growth was offset by lower net pricing and shifts in wholesale inventory |
| The team has really done a really great job this year with Xifaxan and getting the growth on it, and then the unmet need that is still there in both the IBS-D side of the business and the HE side of the business, there’s still an unmet need that we can treat more patients |
| If you look at the data that we saw in the fourth quarter as we exited the year, the data was strong, and so those tools are really going to help us move forward with Xifaxan |
| We saw growth in TRx for IBS-D and, importantly, we also saw solid growth of approximately 6% year-over-year in Q4 in TRx for the long term care channel, as well as strong growth in non-retail units attributable to outpatient clinics |
| Xifaxan continued to represent approximately 80% of Salix segment revenues this year and saw strong growth in underlying demand |
| This was led by strong growth for IBS-D with a return to growth for HE, driven by long term care channel |
| Putting this all together, we believe we are starting to see the benefits our investments in AI-enabled sales force tools and DTC advertising to spread awareness of the underlying medical conditions and the options that are available to treat them |
| Overall, we are pleased that revenues, adjusted EBITDA and adjusted operating cash flow for 2023 for Bausch Health excluding B&L met or exceeded expectations |
| Finally, Trulance and Relistor continued to deliver double-digit TRx growth in the quarter |
| Turning to international, we saw strong year-over-year revenue growth on both a reported and organic basis in all regions during the fourth quarter |
| We made significant progress on these priorities in 2023, reinforcing our strong global foundation which consists of a large portfolio of products across a diverse set of therapeutic areas and geographies |
| For Solta, we anticipate strong double digit organic revenue growth across all major geographies |
| In summary, as you heard today, we made significant progress against our 2023 strategic priorities, and we enter 2024 with strong momentum and a clear set of objectives |
| I really think these two programs give us a really good momentum on our R&D programs as we look forward |
| We believe Solta is poised for long term growth with Thermage FLX in China and untapped potential in the U.S |
| The broad portfolio of products and geographies in our international business will continue to provide balanced growth and in our diversified business, we believe dermatology with the launch of Cabtreo and dentistry will deliver growth, with the remainder of the portfolio remaining profitable and cash generative in a challenging competitive and regulatory environment |
| Our significant presence in gastroenterology, hepatology, neurology, dermatology, medical esthetic devices and international pharmaceuticals across the branded, generic, and branded generic markets gives us a solid platform for growth as we are excited about the opportunities in each of these areas |
| Importantly, we ended the year on a strong note as the fourth quarter represented our third consecutive quarter of year-over-year growth in adjusted EBITDA, and we delivered adjusted operating cash flow of $708 million above our guidance |
| Statement |
|---|
| In dermatology, revenue declined by 12% for the quarter relative to the prior year as volume increases for Jublia and Arazlo were offset by continued net pricing pressures and continued pressure on our non-promoted products |
| For Bausch Health excluding B&L, adjusted gross margin for the fourth quarter was 80.2%, approximately 30 basis points lower than last year’s fourth quarter |
| For the full year, adjusted gross margin was 80.1%, a decline of 50 basis points, which included the impact of the Emerade recall earlier in the year |
| For the year, diversified segment revenues declined 4% on a reported basis and 3% on an organic basis relative to the prior year, with varying degrees of declines in neurology, dermatology and generics reflecting the pressures we’ve discussed throughout the year |
| For diversified, we expect an overall mid single digit decline in organic revenue |
| As already been noted, there are two other S1P receptor modulators approved for UC, but their market reception so far has been lukewarm |
| declined slightly in the quarter |
| The generics business continues to be a profitable cash generative business; however, it also faces a highly competitive environment from both a pricing and volume standpoint |
| Please refer to our SEC filings and filings with the Canadian securities administrators for a list of some of the risk factors that could cause our actual results to differ materially from our expectations |
| While it plays a role with our LOE products, with the timeline of many of those LOEs and the competitive environment we expect to face for the long term, we have revised our expectations for this business and recorded an impairment of goodwill of $91 million in the quarter |
| As we noted then, we saw an increase in wholesale channel inventory in Q3, earlier than we had anticipated, and this quarter we saw inventory in the wholesale channel decline compare to a build in Q4 of 2022 |
| It’s possible, right - the wholesalers have their own algorithms for how and when they buy, but it’s possible that if we see that revert back a little, that it could temper some of the benefit from a revenue standpoint of the underlying demand growth |
| slightly declined compared to the prior year |
| As discussed on our third quarter 2023 earnings call, on October 6, 2023 the DC District Court held a hearing in Norwich’s lawsuit against the FDA, where Norwich was seeking immediate approval of their ANDA |
Please consider a small donation if you think this website provides you with relevant information